"Despite the risk of cancellations and the uncertainty inthe market, Wartsila's prospects for 2009 remain unchanged,"Chief Executive Ole Johansson said in the statement. (Reporting by Brett Young; Editing by Dan Lalor and RupertWinchester) ($1 = 0.7592 euro). Well, that certainly was exciting.Fulham, on the verge of relegation now for months, managed to continue its run to remain in the Premier League by blanking relegation rival Birmingham City 2-0.Fulham won only four games in their first 33, but have miraculously taken three of the last four and now sit just above the relegation zone with one game left to play.Craven Cottage’s hero in its must-win against Birmingham yesterday? None other than American captain Brian McBride, whose second half goal resulted in complete frenzy among the Cottagers’ faithful.McBride scored on a header that was delivered to him with precision by Jimmy Bullard. Fulham added another late goal, but it was McBride’s game winner that will be remembered.The good news? Despite not winning back-to-back games in nearly two seasons, Fulham did just that on Saturday to move above Birmingham City and Reading and out of the relegation zone.The bad news? Well, Fulham is still not safe There is still work to be done. Though Fulham controls its own destiny next Sunday, there are still plenty of scenarios that could result in their expulsion from the EPL.Bolton’s win yesterday makes them statistically safe from relegation (barring a Nintendo-style 14-0 loss to Chelsea), meaning only one of the three remaining relegation rivals (Fulham, Reading and Birmingham City) will stay in the Prem.Birmingham City drew Blackburn for the final game of the year, a tough match up.Meanwhile, Reading plays Derby away, a match they should win, meaning Fulham will likely have to beat Portsmouth ( Portsmouth) on Sunday to remain in the EPL.

With Fulham ahead on goal differential, if the two teams both complete the season at 36 points, the Cottagers would stay in the Prem.On the bright side, Portsmouth is likely to rest some players this weekend for next week’s FA Cup Final, so Fulham may not have to deal with some of their more valuable players.On the down side though is the fact Reading is almost sure to beat the pants off Derby, the worst side to take the pitch in the Premier League in decades, if not ever.So, despite a historic run to avoid relegation, Fulham is clinging to the bottom of the Prem with one game left to play. While Fulham controls their own destiny, a tough battle awaits this Sunday, one that could result in the Cottagers’ disappearance.One thing is for sure going into the season’s final week. Brian McBride, Clint Dempsey and the rest of the Cottagers have never been such huge fans of lowly Derby County.Social Bookmarking. STOCKHOLM, Sweden--(Business Wire)--Regulatory News: Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing44th Annual Meeting of the European Association for the Study of the Liver(EASL) in Copenhagen, Denmark, April 22-26. TMC435 is an investigational protease inhibitor, being developed by Tibotec incollaboration with Medivir (STO:MVIRB), for the treatment of hepatitis C virus(HCV). Data for TMC435 in treatment naïve genotype-1 HCV patients have been presentedin an oral lecture. Furthermore, data in patients with genotype-1 HCV infectionwho failed previous IFN-based therapy were presented during a late breakerposter session.

TMC435 in treatment-naïve genotype-1 HCV patientsThe results from 25, 75 and 200 mg in treatment-naive patients are summarizedbelow: 1. Viral load reduction, (RNA log10 IU/mL), at week 4 on triple therapy groups(SoC and TMC435) was 5.5 and 5.4 log10 IU/mL for the 75 mg and 200 mg TMC435, QDrespectively 2. Undetectable levels (< 10 IU/mL) in 8/9 patients in the 75 mg group and 7/10in the 200 mg group was observed after 4 weeks of treatment with triple therapy.3. After 12 weeks (4 weeks triple + 8 weeks SoC), 6/9, 9/9 and 10/10 hadundetectable virus (< 10 IU/mL) in the 25mg, 75 and 200 mg groups, respectively.4. No breakthroughs observed after 4 weeks of triple therapy in any of thegroups (25, 75 or 200 mg) 5. No treatment related discontinuations, most AEs were mild to moderate 6.